Bread recalled after glass found on top of bread sold: See affected states
Show Caption
Hide Caption
FDA will reduce food and drug inspections due to federal layoffs
FDA scales back routine inspections due to support staff layoffs, prioritizing high-risk cases amid government restructuring and budget cuts.
Straight Arrow News
Bread sold in six different states has been voluntarily recalled after fragments of glass were found on top of the bread, the Food and Drug Administration has announced.
The bread, sold by the Maryland-based company Upper Crust Crest Hill Bakery, listed as "Upper Crust Bakery LP," by the FDA, was recalled on April 12, according to an enforcement report by the FDA.
The bakery, also known as the Crest Hill Bakery, sells partially baked bread and frozen pizza dough it makes with "non-genetically modified ingredients," that it then sells to major food retailers and wholesalers, according to its website.
USA TODAY has reached out to Upper Crust Crest Hill Bakery and the FDA for more information.
Recall alert: Nearly 19K pounds of ready-to-eat meat products recalled due to high 'sodium levels'
What was recalled?
Can't see the graph? Click here.
Three different types of breads sold by the company are being recalled:
Ancient Grains Hoagie Roll
Multigrain Sourdough
Whole Grain Multigrain
Where was the recalled bread sold?
The bread was sold in the following states, according to the FDA:
California
Connecticut
Delaware
Maryland
Ohio
Pennsylvania
A list of stores where the recalled bread was sold was not available on the FDA's enforcement report.
Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn,X, Instagram and TikTok: @juliamariegz, or email her at jgomez@gannett.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
26 minutes ago
- Bloomberg
FDA Weighs Pulling Pfizer's Covid Vaccine for Kids Under Age 5
The Food and Drug Administration is considering revoking Pfizer Inc. 's authorization to sell its Covid vaccine for children under the age of 5, a move that would leave healthy kids with no available shots. The agency told Pfizer it might not renew the pandemic-era authorization covering the youngest children, the company said in a statement. Pfizer has requested the authorization stay in place through the coming fall season and is 'currently in discussions with the agency on potential paths forward,' the company said.
28 minutes ago
Officials are investigating the cause of a Pennsylvania steel plant explosion that killed 2
CLAIRTON, Pa. -- An explosion rocked a steel plant outside Pittsburgh, leaving two dead and 10 others injured, including a person who was rescued from the smoldering rubble after hours of being trapped. The explosion sent black smoke spiraling into the midday Monday sky in the Mon Valley, a region of the state synonymous with steel for more than a century. Allegheny County Emergency Services said a fire at the plant in Clairton started late Monday morning. Officials said they had not isolated the cause of the blast. The rumbling from the explosion, and several smaller blasts that followed, jolted the community about 15 miles (24 kilometers) southeast of Pittsburgh. Amy Sowers, who was sitting on her porch less than a mile from the plant, felt her house shake. 'I could see smoke from my driveway,' she said. 'We heard ambulances and fire trucks from every direction.' Sowers, 45, grew up in Clairton and has seen several incidents at the plant over the years. 'Lives were lost again,' Sowers said. 'How many more lives are going to have to be lost until something happens?' At a news conference, Scott Buckiso, U.S. Steel's chief manufacturing officer, did not give details about the damage or casualties, and said they were still trying to determine what happened. He said the company, now a subsidiary of Japan-based Nippon Steel Corp., is working with authorities. Allegheny Health Network said it treated seven patients from the plant and discharged five within a few hours. University of Pittsburgh Medical Center said it is treating three patients at UPMC Mercy, the region's only level one trauma and burn center. According to the company, the plant has approximately 1,400 workers. In a statement, the United Steelworkers, which represents many of the Clairton plant's workers, said it had representatives on the ground at the plant and would work to ensure there is a thorough investigation. David Masur, executive director of PennEnvironment, an environmental group that has sued U.S. Steel over pollution, said there needed to be 'a full, independent investigation into the causes of this latest catastrophe and a re-evaluation as to whether the Clairton plant is fit to keep operating.' U.S. Steel CEO David B. Burritt said the company would investigate. It's not the first explosion at the plant. A maintenance worker was killed in a blast in September 2009. In July 2010, another explosion injured 14 employees and six contractors. According to online OSHA records of workplace fatalities, the last death at the plant was in 2014, when a worker was burned and died after falling into a trench. After the 2010 explosion, the Occupational Safety and Health Administration fined U.S. Steel and a subcontractor $175,000 for safety violations. U.S. Steel appealed its citations and fines, which were later reduced under a settlement agreement. In February, a problem with a battery at the plant led to a 'buildup of combustible material' that ignited, causing an audible 'boom,' officials said. Two workers received first aid treatment but were not seriously injured. The plant, a massive industrial facility along the Monongahela River, is considered the largest coking operation in North America and is one of four major U.S. Steel plants in Pennsylvania. The plant converts coal to coke, a key component in the steelmaking process. To make coke, coal is baked in special ovens for hours at high temperatures to remove impurities that could otherwise weaken steel. The process creates what's known as coke gas — made up of a lethal mix of methane, carbon dioxide and carbon monoxide. The county health department initially told residents within 1 mile (1.6 kilometers) of the plant to remain indoors and close all windows and doors, but lifted the advisory later Monday. It said its monitors didn't detect levels of soot or sulfur dioxide above federal standards. U.S. Steel has been a symbol of industrialization since it was founded in 1901 by J.P. Morgan, Andrew Carnegie and others. It's been the icon of the American steel industry that once dominated the world market until Japan, then China, became preeminent steelmakers over the past 40 years. In June, U.S. Steel and Nippon Steel announced they had finalized a 'historic partnership,' a deal that gives the U.S. government a say in some matters and comes a year and a half after the Japanese company first proposed its nearly $15 billion buyout of the iconic American steelmaker. The pursuit by Nippon Steel for the Pittsburgh-based company was buffeted by national security concerns and presidential politics in a premier battleground state, dragging out the transaction for more than a year after U.S. Steel shareholders approved it. ___
Yahoo
30 minutes ago
- Yahoo
IO Biotech to pursue cancer vaccine approval despite Phase III miss
IO Biotech's lead cancer vaccine asset, Cylembio (imsapepimut and etimupepimut, adjuvant), has narrowly missed its primary endpoint of improved PFS in a Phase III clinical trial in advanced melanoma. Despite this topline outcome, IO Biotech still plans to submit a biologics license application (BLA) to the US Food and Drug Administration (FDA) for Cylembio in an advanced melanoma setting by the end of 2025, said the company's CEO, Mai-Britt Zocca, during an investor call on 11 August. Investors were seemingly not convinced by IO Biotech's plans for Cylembio, with the company's stock dropping by 27% after the call, from $1.88 at market open on 11 August to $1.37 at 12 pm Eastern Time (ET) on the same day. If approved, Cylembio would be the first cancer vaccine to get the FDA green light in an advanced melanoma patient population. The Phase III IOB-013/KN-D18 trial (NCT05155254) compared the efficacy and safety of Cylembio in combination with Merck's Keytruda (pembrolizumab) versus Keytruda alone. The trial found that the combination therapy offered a median PFS (mPFS) benefit of 19.4 months versus 11 months with Keytruda alone. While the combination reduced the risk of disease progression or death by 23%, the result was not statistically significant, with a p-value of 0.056 compared to the desired p≤0.045. Though not mature, a trend in overall survival (OS) improvement has also been observed, with the OS data reading out in the next six months. Notably, a post-hoc analysis conducted in patients without prior anti-PD-1 treatment showed that Cylembio plus Keytruda offered significant improvements in mPFS values, increasing from 19.4 months to 24.8 months. During the call, investors voiced concerns around the number of patients recruited in the US for this study, which stood at 17 of the 407 enrolled, with questions asked about whether the FDA could ask for a second trial for better US patient representation. IO's CMO, Qasim Ahmad, dismissed these claims, stating that the biotech 'does not see any risk adherent to these parts of our filings,' due to its ongoing conversations with the regulator on the execution of this trial. Ahmad also stated that 90% of the trial's participants were Caucasian, Western European patients, which IO believes will satisfy the agency with their requirements of trials that represent the US population. Cancer vaccine race is on Though there is a wide range of drugs approved for the treatment of melanoma, patients with unresectable, advanced iterations of the disease often experience poor outcomes, with 50% of patients relapsing within the first year of treatment with standard of care (SoC) Keytruda. This means that many pharma companies are aiming to fulfil the unmet need of refractory patients, with GlobalData's Intelligence Centre (IC) revealing there are 2,308 ongoing clinical trials within the melanoma space currently. Despite the competitive nature of the melanoma market, analysts at GlobalData, parent company of Clinical Trials Arena, forecast that Cylembio could make $495m by 2031 if approved. According to Zocca, the company will support the timely rollout of Cylembio if approved through its commercial-scale manufacturing and global supply chain, which is 'already in place'. IO may face stiff competition with Moderna and MSD's vaccine candidate, mRNA-4157, which is hot on Cylembio's tail, currently being investigated in Phase III trials for advanced melanoma. If approved, mRNA-4157 would be a significant competitor of Cylembio, as the jab is personalised to the user's tumour microenvironment, while the latter can only kill tumour and immune-suppressive cells expressing indoleamine 2,3-dioxygenase 1 (IDO1) positive and/or programmed death-ligand 1 (PD-L1). "IO Biotech to pursue cancer vaccine approval despite Phase III miss" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
